Loading stock…

AbbVie Inc. (ABBV) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

ABBVAbbVie

Revenue FY25$61.2B

GROWTH RATING↗

AVERAGE57 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%3

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+495%10

EPS growth, FY27E+16%8

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 2%/yr over the last 3 years and is set to grow 9%/yr from here.

Earnings are set to grow faster than sales (EPS about 16%/yr vs revenue 9%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 57% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Revenue grew 2%/yr over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's speeding up. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG94 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+8%8

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high99%10

1-year return+21%7

3-year return+103%8

5-year return+193%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +103% over three years and +193% over five, ahead of 80% of the market.

It's up 21% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+9%), over three months (+8%) and so far this year (+22%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on AbbVie. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ABBVAbbVie

Revenue FY25$61.2B

GROWTH RATING↗

AVERAGE57 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%3

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%6

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+495%10

EPS growth, FY27E+16%8

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 2%/yr over the last 3 years and is set to grow 9%/yr from here.

Earnings are set to grow faster than sales (EPS about 16%/yr vs revenue 9%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 57% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Revenue grew 2%/yr over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's speeding up. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG94 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+8%8

YTD return+22%8

MID & LONG-TERM▾SCORE

% of 52-week high99%10

1-year return+21%7

3-year return+103%8

5-year return+193%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +103% over three years and +193% over five, ahead of 80% of the market.

It's up 21% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+9%), over three months (+8%) and so far this year (+22%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on AbbVie. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

AbbVie Inc.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on AbbVie. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on AbbVie. Get the full investment case.

Premium